Association of dopamine gene variants, emotion dysregulation and ADHD in autism spectrum disorder.
The aim of the present study was to evaluate the association of dopaminergic gene variants with emotion dysregulation (EMD) and attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorder (ASD). Three dopamine transporter gene (SLC6A3/DAT1) polymorphisms (intron8 5/6 VNTR, 3'-UTR 9/10 VNTR, rs27072 in the 3'-UTR) and one dopamine D2 receptor gene (DRD2) variant (rs2283265) were selected for genotyping based on à priori evidence of regulatory activity or, in the case of DAT1 9/10 VNTR, commonly reported associations with ADHD. A sample of 110 children with ASD was assessed with a rigorously validated DSM-IV-referenced rating scale. Global EMD severity (parents' ratings) was associated with DAT1 intron8 (ηp(2)=.063) and rs2283265 (ηp(2)=.044). Findings for DAT1 intron8 were also significant for two EMD subscales, generalized anxiety (ηp(2)=.065) and depression (ηp(2)=.059), and for DRD2 rs2283265, depression (ηp(2)=.053). DRD2 rs2283265 was associated with teachers' global ratings of ADHD (ηp(2)=.052). DAT1 intron8 was associated with parent-rated hyperactivity (ηp(2)=.045) and both DAT1 9/10 VNTR (ηp(2)=.105) and DRD2 rs2283265 (ηp(2)=.069) were associated with teacher-rated inattention. These findings suggest that dopaminergic gene polymorphisms may modulate EMD and ADHD symptoms in children with ASD but require replication with larger independent samples.
Department of Psychiatry, Stony Brook University, Stony Brook, NY 11794-8790, United States. Electronic address: kenneth.gadow@stonybrook.edu.
Kenneth D
KD
Gadow
Department of Pharmacology, Center in Pharmacogenomics, Ohio State University Wexner Medical Center, 333 West 10th Avenue, Columbus 43210, United States. Electronic address: pinsonneault.2@osu.edu.
Julia K
JK
Pinsonneault
Department of Psychiatry, Stony Brook University, Stony Brook, NY 11794-8790, United States. Electronic address: gperlman@gmail.com.
Greg
G
Perlman
Department of Pharmacology, Center in Pharmacogenomics, Ohio State University Wexner Medical Center, 333 West 10th Avenue, Columbus 43210, United States. Electronic address: Wolfgang.Sadee@osumc.edu.
Wolfgang
W
Sadee
D000293:Adolescent; D000342:Affective Symptoms / Q000175:diagnosis / Q000235:genetics* / Q000523:psychology; D001008:Anxiety Disorders / Q000175:diagnosis / Q000235:genetics / Q000523:psychology; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000235:genetics* / Q000523:psychology; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000175:diagnosis / Q000235:genetics* / Q000523:psychology; D002675:Child, Preschool; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000235:genetics / Q000523:psychology; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics*; D056348:Emotional Intelligence / Q000235:genetics*; D005260:Female; D014644:Genetic Variation / Q000235:genetics*; D005838:Genotype; D006801:Humans; D007438:Introns / Q000235:genetics; D008297:Male; D018598:Minisatellite Repeats / Q000235:genetics; D017448:Receptors, Dopamine D2 / Q000235:genetics*
C581293:DRD2 protein, human; D050483:Dopamine Plasma Membrane Transport Proteins; D017448:Receptors, Dopamine D2; C493214:SLC6A3 protein, human
ADHD; Autism; Autism spectrum disorder; DAT1; DRD2; Depression; Emotion dysregulation